Tag Archives: Ryan Zimmerman

Organogenesis Holdings Inc (ORGO) Receives a Buy from BTIG

BTIG analyst Ryan Zimmerman maintained a Buy rating on Organogenesis Holdings Inc (ORGO – Research Report) yesterday and set a price target of $12. The company’s shares closed yesterday at $8.43, close to its 52-week low of $6.28. Zimmerman said:

SeaSpine Holdings (SPNE) Receives a Buy from BTIG

BTIG analyst Ryan Zimmerman reiterated a Buy rating on SeaSpine Holdings (SPNE – Research Report) on March 28 and set a price target of $20. The company’s shares closed on Friday at $15.08. Zimmerman wrote: “We reiterate our Buy rating

BTIG Reaffirms Their Buy Rating on OrthoPediatrics Corp (KIDS)

BTIG analyst Ryan Zimmerman maintained a Buy rating on OrthoPediatrics Corp (KIDS – Research Report) today and set a price target of $37. The company’s shares closed on Monday at $34.88. Zimmerman commented: “PT to $37 We are raising our

BTIG Maintains a Buy Rating on Stryker Corporation (SYK)

BTIG analyst Ryan Zimmerman maintained a Buy rating on Stryker Corporation (SYK – Research Report) yesterday and set a price target of $187. The company’s shares closed yesterday at $164.34. According to TipRanks.com, Zimmerman is a 5-star analyst with an

BTIG Keeps a Hold Rating on Zimmer Biomet Holdings (ZBH)

BTIG analyst Ryan Zimmerman maintained a Hold rating on Zimmer Biomet Holdings (NYSE: ZBH) on October 26. The company’s shares closed on Friday at $115.13. Zimmerman noted: “an easy comp led us to believe that 3Q results were beatable. While

Analysts’ Top Healthcare Picks: Stryker Corporation (SYK), Ultragenyx (RARE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Stryker Corporation (NYSE:SYK) and Ultragenyx (NASDAQ:RARE) with bullish sentiments. Stryker Corporation (SYK) BTIG analyst Ryan Zimmerman maintained a Buy rating on Stryker